Novel mode of action

Based on the available data, Topotarget believes that belinostat has the potential to become the best in class HDAC inhibitor. Belinostat can be administered intravenously and orally. This adds to the flexibility in the clinical setting, albeit the intravenous administration appears to enable high blood concentrations of the drug not previously seen in with orally admistered HDAC inhibitors. The drug has demonstrated a favorable safety profile compared to other HDAC inhibitors at a similar stage of development. This allows for a combination of belinostat at full dose with a full dose of chemotherapy, thereby maximizing clinical effect.